Երկիր: Կանադա
Լեզու: անգլերեն
Աղբյուրը: Health Canada
BICALUTAMIDE
SIVEM PHARMACEUTICALS ULC
L02BB03
BICALUTAMIDE
50MG
TABLET
BICALUTAMIDE 50MG
ORAL
30/100
Prescription
ANTINEOPLASTIC AGENTS
Active ingredient group (AIG) number: 0127996001; AHFS:
CANCELLED POST MARKET
2020-01-22
PRODUCT MONOGRAPH PR BICALUTAMIDE Bicalutamide tablets, USP 50 mg Tablets Non-Steroidal Anti-androgen Sivem Pharmaceuticals ULC 4705 Dobrin Street Saint-Laurent, Quebec H4R 2P7 www.sivem.ca Date of Revision: January 23, 2018 Submission Control No.: 212723 _BICALUTAMIDE Product Monograph_ Page 2 of 34 TABLE OF CONTENTS PART I: HEALTH PROFESSIONAL INFORMATION .......................................................... 3 SUMMARY PRODUCT INFORMATION ........................................................................ 3 INDICATIONS AND CLINICAL USE ............................................................................. 3 CONTRAINDICATIONS ................................................................................................... 3 WARNINGS AND PRECAUTIONS ................................................................................. 4 ADVERSE REACTIONS ................................................................................................... 8 DRUG INTERACTIONS .................................................................................................. 12 DOSAGE AND ADMINISTRATION.............................................................................. 13 OVERDOSAGE ................................................................................................................ 13 ACTION AND CLINICAL PHARMACOLOGY ............................................................ 13 STORAGE AND STABILITY ......................................................................................... 14 DOSAGE FORMS, COMPOSITION AND PACKAGING ............................................. 14 PART II: SCIENTIFIC INFORMATION ................................................................................ 15 PHARMACEUTICAL INFORMATION ......................................................................... 15 CLINICAL TRIALS ......................................................................................................... 16 DETAILED PHARMACOLOGY............................................. Կարդացեք ամբողջական փաստաթուղթը